This stock was set up for a fall by a flood of negative posts over the weekend, followed by two SA pieces pumping a potential competitor. Another example of the importance of reading up on the science behind a biotech before you decide to invest or bail out.
It was definitely orchestrated. We were hit by a team of short sellers/publishers, who strategically instilled doubt after a nice run up. To be honest, they found a great target, and by the close today, they will have covered 1/3 - 1/2 their position to lock in 10%+ gains. The execution was well planned, and I take my hat off to the team. Picking a single weak point about the AMR-001 published study and implying a blanket failure without actually mentioning all the positive improvments to heart function. Then suggesting another company has the complete solution. Having the crazy crowd post follow-up lies is making it look even more insane today.
Big pharma is getting people's shares cheap. That is all I can say. People are not wise to sell right now for no reason. That study using a different cell population than Amorcyte was actually very very good news if you understand the science of myocardial infarctions or just science in general